CDK4 and breast carcinoma: Next, a recent trial has shown a correlation between macrophage abundance and cyclin E levels in metastatic ER-positive/HER2-negative breast cancer patients, suggesting that the immune TME may be useful in predicting CDK4/6 inhibitor efficacy [130].